U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07136077) titled 'A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy' on Aug. 18.
Brief Summary: To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have "positive" ctDNA tests for MRD (meaning there is evidence of MRD based on this test).
Study Start Date: Feb. 05, 2026
Study Type: INTERVENTIONAL
Condition:
Minimal Residual Disease
Adjuvant Chemotherapy
Colorectal Cancer
Fruquintinib
Tislelizumab
ctDNA
Intervention:
DRUG: Tislelizumab
Given by IV
DRU...